Canaccord Genuity Group Forecasts Strong Price Appreciation for CeriBell (NASDAQ:CBLL) Stock

CeriBell (NASDAQ:CBLL) had its price target boosted by equities researchers at Canaccord Genuity Group from $30.00 to $31.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 12.52% from the stock’s previous close.

CBLL has been the subject of several other research reports. TD Cowen initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $31.00 price objective for the company. Canaccord Genuity Group initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price objective for the company. Bank of America initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price objective for the company. Finally, William Blair initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CeriBell has an average rating of “Buy” and a consensus target price of $31.20.

CeriBell Price Performance

Shares of CeriBell stock opened at $27.55 on Wednesday. CeriBell has a 52-week low of $23.00 and a 52-week high of $29.53.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. On average, equities research analysts predict that CeriBell will post -1.55 EPS for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.